iBio, Inc. (IBIO) stock
IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.73−0.03 (-4.00%)
Close on Nov 13, 2026Market cap $47.05MP/E –Yield –
iBio EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
iBio's EPS for the twelve months ending Sep 30, 2026 was -$0.27. For fiscal 2026 it was -$0.32. The highest annual figure on record is -$0.32 in fiscal 2026.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$0.32 | – |
| FY2025 | Jun 30, 2025 | -$1.75 | – |
| FY2024 | Jun 30, 2024 | -$6.50 | – |
| FY2023 | Jun 30, 2023 | -$106.19 | – |
| FY2022 | Jun 30, 2022 | -$115.60 | – |
| FY2021 | Jun 30, 2021 | -$60.00 | – |
| FY2020 | Jun 30, 2020 | -$305.00 | – |
| FY2019 | Jun 30, 2019 | -$470.00 | – |
| FY2018 | Jun 30, 2018 | -$770.00 | – |
| FY2017 | Jun 30, 2017 | -$820.00 | – |
| FY2016 | Jun 30, 2016 | -$600.00 | – |
| FY2015 | Jun 30, 2015 | -$450.00 | – |
| FY2014 | Jun 30, 2014 | -$300.00 | – |
| FY2013 | Jun 30, 2013 | -$650.00 | – |
| FY2012 | Jun 30, 2012 | -$700.00 | – |
| FY2011 | Jun 30, 2011 | -$1950.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$0.05 | – |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$0.07 | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$0.06 | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$0.09 | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$0.11 | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$0.36 | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$0.49 | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$0.48 | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$0.46 | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$0.85 | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$4.42 | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$4.80 | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$5.75 | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$11.07 | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$68.43 | -57125.0% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$41.00 | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$23.80 | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$28.40 | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $0.12 | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$20.00 | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$20.00 | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$25.00 | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$30.00 | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$345.00 | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$105.00 | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$114.70 | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$110.00 | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$120.00 | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$125.00 | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$190.23 | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$175.00 | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$205.00 | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$210.00 | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$246.49 | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$200.00 | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$200.00 | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$150.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?